Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT06468956
PHASE3
Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis
Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
View on ClinicalTrials.gov
Summary
This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with atopic dermatitis.
Official title: A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR-1819 Injection in Patients With Moderate to Severe Atopic Dermatitis
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
652
Start Date
2024-06-14
Completion Date
2026-03-31
Last Updated
2025-09-11
Healthy Volunteers
No
Conditions
Interventions
DRUG
SHR-1819
SHR-1819 injection
DRUG
Placebo
placebo
Locations (1)
Shanghai Fudan University HuaShan Hospital
Shanghai, Shanghai Municipality, China